Neurogene Inc

Neurogene Inc has a strong liquidity position, with a current ratio of 16.56, indicating that the company has significantly more current assets than current liabilities. The company holds $103.85 million in cash and equivalents, which is a substantial portion of its total assets of $288.60 million. The debt-to-equity ratio is 0.0, suggesting that the company is not leveraged and relies primarily on equity financing. The company is currently unprofitable, with a net loss of $90.35 million and an operating loss of $103.33 million. Its return on equity (ROE) is -34.11%, and its return on assets (ROA) is -31.31%, both significantly below the industry median for biotechnology firms. These metrics indicate that the company is not generating returns for its shareholders and is underperforming in asset utilization. Neurogene Inc does not disclose specific revenue by geographic region or business segment in the available data. However, the absence of disclosed revenue by segment suggests that the company may be in an early stage of development or may not have diversified its product offerings. The company's revenue is reported as $0.00, indicating that it is not yet generating revenue from its operations. The company's outlook for the current fiscal year is negative, with no revenue reported and a net loss of $90.35 million. The operating cash flow is negative at $77.17 million, and the free cash flow is also negative at $88.49 million. These figures suggest that the company is not yet generating positive cash flows from its operations and is likely relying on external financing to fund its activities. The risk assessment for Neurogene Inc indicates low liquidity and dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is low. The company's capital structure is primarily equity-based, with no long-term debt, which reduces the risk of financial distress. However, the company's negative cash flows and lack of revenue could pose a risk to its long-term sustainability. Recent events related to Neurogene Inc include analyst estimates that suggest a wide range of price targets, with a mean of $76.43 and a median of $69.00. The high price target is $180.00, while the low is $46.00. The mean recommendation is 1.56, indicating a generally positive outlook from analysts, with 4 strong-buy and 5 buy ratings. These analyst estimates suggest that there is optimism about the company's future potential, despite its current financial challenges.